The U.S. Food and Drug Administration approved Ann Arbor, Michigan-based Esperion’s Nexlizet (bempedoic acid and ezetimibe) for lowering LDL cholesterol.
Novartis’ QMF149 met primary and key secondary endpoints in the Phase III QUARTZ clinical trial for asthma.
